SlideShare uma empresa Scribd logo
1 de 8
Baixar para ler offline
Reports Corner

THERAPEUTIC CLASS OVERVIEW: TREATING REFRACTORY
HEMATOLOGICAL MALIGNANCIES

RC
Description
Description
Targeting unmet needs in the treatment of cancer/ hematological
malignancies through innovative drug development strategies
have witnessed favorable outcomes. Over the past decade,
Proteasome
inhibitor,
Velcade
(bortezomib)
and
the
immunomodulatory drugs – Thalomid (thalidomide) and Revlimid
(lenalidomide) have become the cornerstone of treatment for
patients with Multiple Myeloma (MM) resulting in improved
survival.

www.reportscorner.com

Reports Corner
Brief Summary
Brief Summary
Targeting unmet needs in the treatment of cancer/ hematological
malignancies through innovative drug development strategies
have witnessed favorable outcomes. Over the past decade,
Proteasome
inhibitor,
Velcade
(bortezomib)
and
the
immunomodulatory drugs – Thalomid (thalidomide) and Revlimid
(lenalidomide) have become the cornerstone of treatment for
patients with Multiple Myeloma (MM) resulting in improved
survival. However, eventually all patients relapse and new
treatment options for Relapsed/ Refractory Multiple Myeloma
(RRMM) are required to further improve survival and quality of life
of this group of pts. Two new drugs have successfully fulfilled
this need – POMALYST/ IMNOVID (pomalidomide – POM) and
Kyprolis (carfilzomib-CFZ) but is there room for more?We expect
a similar scenario to unfold in the treatment of Recurrent/
Refractory MDS (RR-MDS, High-Risk MDS), and Relapsed/
Refractory AML (R/R AML).
www.reportscorner.com

Reports Corner
Brief Summary
Brief Summary
Innovative approach to treating unmet need has been handsomely
rewarded in the past through in-licensing or outright acquisition
of the mature/nascent product/innovator company at a premium.
The report provides an overview of the approved therapies for
RRMM, NDMM, AML, MDS, unmet need and limitations of the
current SOC for relapsed and refractory pts. The report highlights
the competition and commercial opportunity in pursuing these
therapy areas – Comprehensive list of the early and late stage
drugs in the clinic, their MoA and the companies developing them.

www.reportscorner.com

Reports Corner
Table of Contents
Table of Contents
Chapters Title Pg No.
1. Executive Summary 33
2. Disease Overview: MDS 34-35
2.1. Unmet Need: MDS
3. Current Standard of Care 35-36
3.1. Supportive Care: Hematopoietic Cytokine
3.2. Low-Intensity Therapy
3.3. High-Intensity Therapy
3.4. Recurrent / Refractory or relapsed MDS
4. Disease Overview: AML 37
5. Current Standard of Care 37-38
5.1. AML pts Younger than 60 years
5.2. AML pts Older than 60 years
6. Unmet Need: AML 38-39
6.1. Relapsed/ refractory AML
www.reportscorner.com

Reports Corner
Table of Contents
Table of Contents
7. Late-Stage pipeline Targeting High-Risk or R/R MDS AND R/R AML 39-48
7.1. Estybon
7.2. Vosaroxin
7.3. Quizartinib
7.4. ADI-PEG 20
7.5. BL-8040
8. Late-Stage pipeline Targeting 1st-line Lower Risk MDS 49-51
8.1. Volasertib
8.2. CPX-351
8.3. Sapacitabine
8.4. Oral Rigosrtib
9. Key Milestones of Drugs For RRMDS/RRAML in 2014-15 52
10. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline (RR MDS and RR AML) 53
11. Drivers of M&A/Licensing Deals in MDS/AML 54
www.reportscorner.com

Reports Corner
For more information
For more information
For more information please visit our website
https://www.reportscorner.com/reports/37924/-THERAPEUTIC-CLASS-OVERVIEW:TREATING-REFRACTORY-HEMATOLOGICAL-MALIGNANCIES/

www.reportscorner.com

Reports Corner
RC

Thank You
Thank You

Contact us: contact@reportscorner.com
www.reportscorner.com

Reports Corner

Mais conteúdo relacionado

Mais procurados

Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple MyelomaEneutron
 
Multiple myeloma
Multiple  myelomaMultiple  myeloma
Multiple myelomaorthoprince
 
Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple MyelomaAlok Kumar
 
Renal Impairment in Multiple Myeloma
Renal Impairment in Multiple MyelomaRenal Impairment in Multiple Myeloma
Renal Impairment in Multiple MyelomaMohammed A Suwaid
 
(Multiple Myeloma) MM
(Multiple Myeloma) MM(Multiple Myeloma) MM
(Multiple Myeloma) MMRawan Adnan
 
Multiple myeloma - Dr Guru
Multiple myeloma - Dr GuruMultiple myeloma - Dr Guru
Multiple myeloma - Dr GuruRsguru Rs
 
Final multiple myeloma
Final multiple myelomaFinal multiple myeloma
Final multiple myelomaipdsiot
 
Multiple myeloma 3
Multiple myeloma  3Multiple myeloma  3
Multiple myeloma 3Jasmine John
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myelomaBSMMU
 
Management of Multiple myeloma
Management of Multiple myelomaManagement of Multiple myeloma
Management of Multiple myelomaorthoprinciples
 
Proteasome inhibitors in treatment of multiple myeloma
Proteasome inhibitors in treatment of multiple myelomaProteasome inhibitors in treatment of multiple myeloma
Proteasome inhibitors in treatment of multiple myelomaAlok Gupta
 
Multiple Myeloma Modified , Dr Gamal Abdul Hamid
Multiple   Myeloma Modified ,  Dr  Gamal  Abdul  HamidMultiple   Myeloma Modified ,  Dr  Gamal  Abdul  Hamid
Multiple Myeloma Modified , Dr Gamal Abdul HamidGamal Abdul Hamid
 
Multiple Myloma Diagnostic Criteria
Multiple Myloma Diagnostic CriteriaMultiple Myloma Diagnostic Criteria
Multiple Myloma Diagnostic CriteriaAhmed Ghany
 
Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple MyelomaAlan Teh
 

Mais procurados (20)

Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple Myeloma
 
Multiple myeloma
Multiple  myelomaMultiple  myeloma
Multiple myeloma
 
Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple Myeloma
 
Renal Impairment in Multiple Myeloma
Renal Impairment in Multiple MyelomaRenal Impairment in Multiple Myeloma
Renal Impairment in Multiple Myeloma
 
(Multiple Myeloma) MM
(Multiple Myeloma) MM(Multiple Myeloma) MM
(Multiple Myeloma) MM
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
Multiple myeloma - Dr Guru
Multiple myeloma - Dr GuruMultiple myeloma - Dr Guru
Multiple myeloma - Dr Guru
 
Final multiple myeloma
Final multiple myelomaFinal multiple myeloma
Final multiple myeloma
 
Multiple myeloma 3
Multiple myeloma  3Multiple myeloma  3
Multiple myeloma 3
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
Management of Multiple myeloma
Management of Multiple myelomaManagement of Multiple myeloma
Management of Multiple myeloma
 
Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple Myeloma
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple Myeloma
 
multiple myeloma
multiple myelomamultiple myeloma
multiple myeloma
 
Proteasome inhibitors in treatment of multiple myeloma
Proteasome inhibitors in treatment of multiple myelomaProteasome inhibitors in treatment of multiple myeloma
Proteasome inhibitors in treatment of multiple myeloma
 
Multiple Myeloma Modified , Dr Gamal Abdul Hamid
Multiple   Myeloma Modified ,  Dr  Gamal  Abdul  HamidMultiple   Myeloma Modified ,  Dr  Gamal  Abdul  Hamid
Multiple Myeloma Modified , Dr Gamal Abdul Hamid
 
Multiple Myloma Diagnostic Criteria
Multiple Myloma Diagnostic CriteriaMultiple Myloma Diagnostic Criteria
Multiple Myloma Diagnostic Criteria
 
Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple Myeloma
 
Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on ...
Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on ...Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on ...
Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on ...
 

Destaque

Amir Almas Resume
Amir Almas ResumeAmir Almas Resume
Amir Almas ResumeAmir Almas
 
Client delight strategies
Client delight strategiesClient delight strategies
Client delight strategiesFaisyal Firdaus
 
2015 Edelman Trust Barometer Japan
2015 Edelman Trust Barometer Japan2015 Edelman Trust Barometer Japan
2015 Edelman Trust Barometer JapanEdelman APACMEA
 
2016 02-09 Future Landscape and Public Realm Conference - Edible Landscapes
2016 02-09 Future Landscape and Public Realm Conference - Edible Landscapes2016 02-09 Future Landscape and Public Realm Conference - Edible Landscapes
2016 02-09 Future Landscape and Public Realm Conference - Edible LandscapesWalter Bone, RLA ASLA
 
Ipsos - Online Audience Consumption Habits 2013
Ipsos - Online Audience Consumption Habits 2013Ipsos - Online Audience Consumption Habits 2013
Ipsos - Online Audience Consumption Habits 2013Ipsos
 
2017 Edelman Trust Barometer - Malaysia
2017 Edelman Trust Barometer - Malaysia2017 Edelman Trust Barometer - Malaysia
2017 Edelman Trust Barometer - MalaysiaEdelman APACMEA
 
WWTH 12.0 Mobile Media Consumption in Thailand - Inmobi
WWTH 12.0 Mobile Media Consumption in Thailand - InmobiWWTH 12.0 Mobile Media Consumption in Thailand - Inmobi
WWTH 12.0 Mobile Media Consumption in Thailand - InmobiWeb Wednesday Thailand
 
2016 Earned Brand Australia
2016 Earned Brand Australia2016 Earned Brand Australia
2016 Earned Brand AustraliaEdelman APACMEA
 

Destaque (9)

Amir Almas Resume
Amir Almas ResumeAmir Almas Resume
Amir Almas Resume
 
2015 Earned Brand India
2015 Earned Brand India2015 Earned Brand India
2015 Earned Brand India
 
Client delight strategies
Client delight strategiesClient delight strategies
Client delight strategies
 
2015 Edelman Trust Barometer Japan
2015 Edelman Trust Barometer Japan2015 Edelman Trust Barometer Japan
2015 Edelman Trust Barometer Japan
 
2016 02-09 Future Landscape and Public Realm Conference - Edible Landscapes
2016 02-09 Future Landscape and Public Realm Conference - Edible Landscapes2016 02-09 Future Landscape and Public Realm Conference - Edible Landscapes
2016 02-09 Future Landscape and Public Realm Conference - Edible Landscapes
 
Ipsos - Online Audience Consumption Habits 2013
Ipsos - Online Audience Consumption Habits 2013Ipsos - Online Audience Consumption Habits 2013
Ipsos - Online Audience Consumption Habits 2013
 
2017 Edelman Trust Barometer - Malaysia
2017 Edelman Trust Barometer - Malaysia2017 Edelman Trust Barometer - Malaysia
2017 Edelman Trust Barometer - Malaysia
 
WWTH 12.0 Mobile Media Consumption in Thailand - Inmobi
WWTH 12.0 Mobile Media Consumption in Thailand - InmobiWWTH 12.0 Mobile Media Consumption in Thailand - Inmobi
WWTH 12.0 Mobile Media Consumption in Thailand - Inmobi
 
2016 Earned Brand Australia
2016 Earned Brand Australia2016 Earned Brand Australia
2016 Earned Brand Australia
 

Semelhante a Therapeutic class overview treating refractory hematological malignancies - ReportsCorner

Treating refractory hematological malignancies
 Treating refractory hematological malignancies Treating refractory hematological malignancies
Treating refractory hematological malignanciesMP ADVISORS
 
Targeted therapy.ppt
Targeted therapy.pptTargeted therapy.ppt
Targeted therapy.pptuditnarang
 
multiple myeloma & daratumumab
multiple myeloma & daratumumabmultiple myeloma & daratumumab
multiple myeloma & daratumumabshubham769
 
3 pmprb guidelines case studies presentation april 7 2020 mb
3 pmprb guidelines case studies presentation april 7 2020 mb3 pmprb guidelines case studies presentation april 7 2020 mb
3 pmprb guidelines case studies presentation april 7 2020 mbNatalie Richardson
 
Research report on small molecules in multiple myeloma treatment
Research report on small molecules in multiple myeloma treatmentResearch report on small molecules in multiple myeloma treatment
Research report on small molecules in multiple myeloma treatmentJamia Hamdard
 
Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multi...
Optimizing Treatment Sequencing  for Patients With Relapsed/ Refractory Multi...Optimizing Treatment Sequencing  for Patients With Relapsed/ Refractory Multi...
Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multi...i3 Health
 
Mantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinicMantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinicspa718
 
CAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORSCAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORSClaire Roudot
 
Rheumatoid arthritis in the latin american context.punta cana 2011
Rheumatoid arthritis in the latin american context.punta cana 2011Rheumatoid arthritis in the latin american context.punta cana 2011
Rheumatoid arthritis in the latin american context.punta cana 2011Carlo V Caballero Uribe MD
 
Multiple Myeloma by Dr Soumya KS
Multiple Myeloma by Dr Soumya KSMultiple Myeloma by Dr Soumya KS
Multiple Myeloma by Dr Soumya KSDr.Soumya KS
 
Cyclin dependent kinase inhibitors competitive landscape, market, & pipe...
Cyclin dependent kinase inhibitors  competitive landscape, market, & pipe...Cyclin dependent kinase inhibitors  competitive landscape, market, & pipe...
Cyclin dependent kinase inhibitors competitive landscape, market, & pipe...DelveInsight Business Research
 
T cell lymphoma
T cell lymphomaT cell lymphoma
T cell lymphomaspa718
 
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...Howard Friedman
 
The Untapped Potential of CAR T Therapy Future Approaches and Case Management...
The Untapped Potential of CAR T Therapy Future Approaches and Case Management...The Untapped Potential of CAR T Therapy Future Approaches and Case Management...
The Untapped Potential of CAR T Therapy Future Approaches and Case Management...RahulJagtap69
 
The Untapped Potential of CAR-T Therapy Future Approaches and Case Management...
The Untapped Potential of CAR-T Therapy Future Approaches and Case Management...The Untapped Potential of CAR-T Therapy Future Approaches and Case Management...
The Untapped Potential of CAR-T Therapy Future Approaches and Case Management...OnkarWeginwar1
 
cancer associated thrombocytopenia.pptx
cancer associated thrombocytopenia.pptxcancer associated thrombocytopenia.pptx
cancer associated thrombocytopenia.pptxMarwa Khalifa
 
Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated ...
Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated ...Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated ...
Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated ...DelveInsight Business Research
 

Semelhante a Therapeutic class overview treating refractory hematological malignancies - ReportsCorner (20)

Treating refractory hematological malignancies
 Treating refractory hematological malignancies Treating refractory hematological malignancies
Treating refractory hematological malignancies
 
Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact...
Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact...Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact...
Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact...
 
Targeted therapy.ppt
Targeted therapy.pptTargeted therapy.ppt
Targeted therapy.ppt
 
multiple myeloma & daratumumab
multiple myeloma & daratumumabmultiple myeloma & daratumumab
multiple myeloma & daratumumab
 
3 pmprb guidelines case studies presentation april 7 2020 mb
3 pmprb guidelines case studies presentation april 7 2020 mb3 pmprb guidelines case studies presentation april 7 2020 mb
3 pmprb guidelines case studies presentation april 7 2020 mb
 
Research report on small molecules in multiple myeloma treatment
Research report on small molecules in multiple myeloma treatmentResearch report on small molecules in multiple myeloma treatment
Research report on small molecules in multiple myeloma treatment
 
Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multi...
Optimizing Treatment Sequencing  for Patients With Relapsed/ Refractory Multi...Optimizing Treatment Sequencing  for Patients With Relapsed/ Refractory Multi...
Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multi...
 
Mantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinicMantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinic
 
CAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORSCAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORS
 
Rheumatoid arthritis in the latin american context.punta cana 2011
Rheumatoid arthritis in the latin american context.punta cana 2011Rheumatoid arthritis in the latin american context.punta cana 2011
Rheumatoid arthritis in the latin american context.punta cana 2011
 
Multiple Myeloma by Dr Soumya KS
Multiple Myeloma by Dr Soumya KSMultiple Myeloma by Dr Soumya KS
Multiple Myeloma by Dr Soumya KS
 
Cyclin dependent kinase inhibitors competitive landscape, market, & pipe...
Cyclin dependent kinase inhibitors  competitive landscape, market, & pipe...Cyclin dependent kinase inhibitors  competitive landscape, market, & pipe...
Cyclin dependent kinase inhibitors competitive landscape, market, & pipe...
 
T cell lymphoma
T cell lymphomaT cell lymphoma
T cell lymphoma
 
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
 
The Untapped Potential of CAR T Therapy Future Approaches and Case Management...
The Untapped Potential of CAR T Therapy Future Approaches and Case Management...The Untapped Potential of CAR T Therapy Future Approaches and Case Management...
The Untapped Potential of CAR T Therapy Future Approaches and Case Management...
 
Blood cancer journal
Blood cancer journalBlood cancer journal
Blood cancer journal
 
The Untapped Potential of CAR-T Therapy Future Approaches and Case Management...
The Untapped Potential of CAR-T Therapy Future Approaches and Case Management...The Untapped Potential of CAR-T Therapy Future Approaches and Case Management...
The Untapped Potential of CAR-T Therapy Future Approaches and Case Management...
 
cancer associated thrombocytopenia.pptx
cancer associated thrombocytopenia.pptxcancer associated thrombocytopenia.pptx
cancer associated thrombocytopenia.pptx
 
Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated ...
Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated ...Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated ...
Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated ...
 
GSK's Jemperli.pdf
GSK's Jemperli.pdfGSK's Jemperli.pdf
GSK's Jemperli.pdf
 

Mais de Reports Corner

Wireless security companies and solutions 2014 - ReportsCorner
Wireless security companies and solutions 2014 - ReportsCornerWireless security companies and solutions 2014 - ReportsCorner
Wireless security companies and solutions 2014 - ReportsCornerReports Corner
 
The cybersecurity market in nigeria to 2023 market brief -
The cybersecurity market in nigeria to 2023 market brief - The cybersecurity market in nigeria to 2023 market brief -
The cybersecurity market in nigeria to 2023 market brief - Reports Corner
 
The global military rotorcraft market 2013 2023 - Reports Corner
The global military rotorcraft market  2013 2023 - Reports CornerThe global military rotorcraft market  2013 2023 - Reports Corner
The global military rotorcraft market 2013 2023 - Reports CornerReports Corner
 
PSA Peugeot Citroen Automotive Company Profile, SWOT and Financial Report...
PSA Peugeot Citroen   Automotive   Company Profile, SWOT and Financial Report...PSA Peugeot Citroen   Automotive   Company Profile, SWOT and Financial Report...
PSA Peugeot Citroen Automotive Company Profile, SWOT and Financial Report...Reports Corner
 
Renewable energy in germany - Reports Corner
Renewable energy in germany - Reports CornerRenewable energy in germany - Reports Corner
Renewable energy in germany - Reports CornerReports Corner
 
Carcinomas – pipeline review, h1 2013 - Reports Corner
Carcinomas – pipeline review, h1 2013 - Reports CornerCarcinomas – pipeline review, h1 2013 - Reports Corner
Carcinomas – pipeline review, h1 2013 - Reports CornerReports Corner
 
Esophageal cancer – pipeline review, h1 2013 - Reports Corner
Esophageal cancer – pipeline review, h1 2013 - Reports CornerEsophageal cancer – pipeline review, h1 2013 - Reports Corner
Esophageal cancer – pipeline review, h1 2013 - Reports CornerReports Corner
 
Textile mills in india - Reports Corner
Textile mills in india - Reports CornerTextile mills in india - Reports Corner
Textile mills in india - Reports CornerReports Corner
 
Immunoglobulins market to 2019 demand in primary immunodeficiency (pi) and ...
Immunoglobulins market to 2019   demand in primary immunodeficiency (pi) and ...Immunoglobulins market to 2019   demand in primary immunodeficiency (pi) and ...
Immunoglobulins market to 2019 demand in primary immunodeficiency (pi) and ...Reports Corner
 
Next generation network oss bss market and forecast 2013-2018 - Reports Corner
Next generation network oss bss market and forecast 2013-2018 - Reports CornerNext generation network oss bss market and forecast 2013-2018 - Reports Corner
Next generation network oss bss market and forecast 2013-2018 - Reports CornerReports Corner
 
The cbrn defense market 2013 2023 - Reports Corner
The cbrn defense market 2013 2023 - Reports CornerThe cbrn defense market 2013 2023 - Reports Corner
The cbrn defense market 2013 2023 - Reports CornerReports Corner
 
Indian in vitro diagnostics market opportunity analysis 2018 - Reports Corner
Indian in vitro diagnostics market opportunity analysis 2018 - Reports CornerIndian in vitro diagnostics market opportunity analysis 2018 - Reports Corner
Indian in vitro diagnostics market opportunity analysis 2018 - Reports CornerReports Corner
 
Pharmaceutical market india a comprehensive industry analysis - Reports Corner
Pharmaceutical market india a comprehensive industry analysis - Reports CornerPharmaceutical market india a comprehensive industry analysis - Reports Corner
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
 
Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner
Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports CornerGlobal pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner
Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports CornerReports Corner
 
Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports Corner
Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports CornerGlobal pharmaceutical & biotechnology outlook 2013 rising stars - Reports Corner
Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports CornerReports Corner
 
Mobile vas markets, applications, and opportunities third edition - Reports...
Mobile vas markets, applications, and opportunities   third edition - Reports...Mobile vas markets, applications, and opportunities   third edition - Reports...
Mobile vas markets, applications, and opportunities third edition - Reports...Reports Corner
 
Annual deal report defense
Annual deal report   defenseAnnual deal report   defense
Annual deal report defenseReports Corner
 
Reports corner new releases
Reports corner   new releasesReports corner   new releases
Reports corner new releasesReports Corner
 
End to-end m2 m, sixth edition
End to-end m2 m, sixth editionEnd to-end m2 m, sixth edition
End to-end m2 m, sixth editionReports Corner
 

Mais de Reports Corner (20)

Wireless security companies and solutions 2014 - ReportsCorner
Wireless security companies and solutions 2014 - ReportsCornerWireless security companies and solutions 2014 - ReportsCorner
Wireless security companies and solutions 2014 - ReportsCorner
 
The cybersecurity market in nigeria to 2023 market brief -
The cybersecurity market in nigeria to 2023 market brief - The cybersecurity market in nigeria to 2023 market brief -
The cybersecurity market in nigeria to 2023 market brief -
 
The global military rotorcraft market 2013 2023 - Reports Corner
The global military rotorcraft market  2013 2023 - Reports CornerThe global military rotorcraft market  2013 2023 - Reports Corner
The global military rotorcraft market 2013 2023 - Reports Corner
 
PSA Peugeot Citroen Automotive Company Profile, SWOT and Financial Report...
PSA Peugeot Citroen   Automotive   Company Profile, SWOT and Financial Report...PSA Peugeot Citroen   Automotive   Company Profile, SWOT and Financial Report...
PSA Peugeot Citroen Automotive Company Profile, SWOT and Financial Report...
 
Renewable energy in germany - Reports Corner
Renewable energy in germany - Reports CornerRenewable energy in germany - Reports Corner
Renewable energy in germany - Reports Corner
 
Carcinomas – pipeline review, h1 2013 - Reports Corner
Carcinomas – pipeline review, h1 2013 - Reports CornerCarcinomas – pipeline review, h1 2013 - Reports Corner
Carcinomas – pipeline review, h1 2013 - Reports Corner
 
Esophageal cancer – pipeline review, h1 2013 - Reports Corner
Esophageal cancer – pipeline review, h1 2013 - Reports CornerEsophageal cancer – pipeline review, h1 2013 - Reports Corner
Esophageal cancer – pipeline review, h1 2013 - Reports Corner
 
Textile mills in india - Reports Corner
Textile mills in india - Reports CornerTextile mills in india - Reports Corner
Textile mills in india - Reports Corner
 
Decription29ththmay
Decription29ththmayDecription29ththmay
Decription29ththmay
 
Immunoglobulins market to 2019 demand in primary immunodeficiency (pi) and ...
Immunoglobulins market to 2019   demand in primary immunodeficiency (pi) and ...Immunoglobulins market to 2019   demand in primary immunodeficiency (pi) and ...
Immunoglobulins market to 2019 demand in primary immunodeficiency (pi) and ...
 
Next generation network oss bss market and forecast 2013-2018 - Reports Corner
Next generation network oss bss market and forecast 2013-2018 - Reports CornerNext generation network oss bss market and forecast 2013-2018 - Reports Corner
Next generation network oss bss market and forecast 2013-2018 - Reports Corner
 
The cbrn defense market 2013 2023 - Reports Corner
The cbrn defense market 2013 2023 - Reports CornerThe cbrn defense market 2013 2023 - Reports Corner
The cbrn defense market 2013 2023 - Reports Corner
 
Indian in vitro diagnostics market opportunity analysis 2018 - Reports Corner
Indian in vitro diagnostics market opportunity analysis 2018 - Reports CornerIndian in vitro diagnostics market opportunity analysis 2018 - Reports Corner
Indian in vitro diagnostics market opportunity analysis 2018 - Reports Corner
 
Pharmaceutical market india a comprehensive industry analysis - Reports Corner
Pharmaceutical market india a comprehensive industry analysis - Reports CornerPharmaceutical market india a comprehensive industry analysis - Reports Corner
Pharmaceutical market india a comprehensive industry analysis - Reports Corner
 
Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner
Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports CornerGlobal pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner
Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner
 
Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports Corner
Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports CornerGlobal pharmaceutical & biotechnology outlook 2013 rising stars - Reports Corner
Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports Corner
 
Mobile vas markets, applications, and opportunities third edition - Reports...
Mobile vas markets, applications, and opportunities   third edition - Reports...Mobile vas markets, applications, and opportunities   third edition - Reports...
Mobile vas markets, applications, and opportunities third edition - Reports...
 
Annual deal report defense
Annual deal report   defenseAnnual deal report   defense
Annual deal report defense
 
Reports corner new releases
Reports corner   new releasesReports corner   new releases
Reports corner new releases
 
End to-end m2 m, sixth edition
End to-end m2 m, sixth editionEnd to-end m2 m, sixth edition
End to-end m2 m, sixth edition
 

Último

Européennes 2024 : projection du Parlement européen à trois mois du scrutin
Européennes 2024 : projection du Parlement européen à trois mois du scrutinEuropéennes 2024 : projection du Parlement européen à trois mois du scrutin
Européennes 2024 : projection du Parlement européen à trois mois du scrutinIpsos France
 
19032024_First India Newspaper Jaipur.pdf
19032024_First India Newspaper Jaipur.pdf19032024_First India Newspaper Jaipur.pdf
19032024_First India Newspaper Jaipur.pdfFIRST INDIA
 
Green Aesthetic Ripped Paper Thesis Defense Presentation_20240311_111012_0000...
Green Aesthetic Ripped Paper Thesis Defense Presentation_20240311_111012_0000...Green Aesthetic Ripped Paper Thesis Defense Presentation_20240311_111012_0000...
Green Aesthetic Ripped Paper Thesis Defense Presentation_20240311_111012_0000...virgfern3011
 
Por estos dos motivos, defensa de JOH solicita repetir juicio
Por estos dos motivos, defensa de JOH solicita repetir juicioPor estos dos motivos, defensa de JOH solicita repetir juicio
Por estos dos motivos, defensa de JOH solicita repetir juicioAlexisTorres963861
 
One India vs United India by Dream Tamilnadu
One India vs United India by Dream TamilnaduOne India vs United India by Dream Tamilnadu
One India vs United India by Dream TamilnaduDreamTamilnadu
 
Light Rail in Canberra: Too much, too little, too late: Is the price worth th...
Light Rail in Canberra: Too much, too little, too late: Is the price worth th...Light Rail in Canberra: Too much, too little, too late: Is the price worth th...
Light Rail in Canberra: Too much, too little, too late: Is the price worth th...University of Canberra
 
Another Day, Another Default Judgment Against Gabe Whitley
Another Day, Another Default Judgment Against Gabe WhitleyAnother Day, Another Default Judgment Against Gabe Whitley
Another Day, Another Default Judgment Against Gabe WhitleyAbdul-Hakim Shabazz
 
Ministry of Justice Extradition Eswatini 3.pdf
Ministry of Justice Extradition Eswatini 3.pdfMinistry of Justice Extradition Eswatini 3.pdf
Ministry of Justice Extradition Eswatini 3.pdfSABC News
 
Anantkumar Hegde
Anantkumar Hegde  Anantkumar Hegde
Anantkumar Hegde NewsFeed1
 

Último (9)

Européennes 2024 : projection du Parlement européen à trois mois du scrutin
Européennes 2024 : projection du Parlement européen à trois mois du scrutinEuropéennes 2024 : projection du Parlement européen à trois mois du scrutin
Européennes 2024 : projection du Parlement européen à trois mois du scrutin
 
19032024_First India Newspaper Jaipur.pdf
19032024_First India Newspaper Jaipur.pdf19032024_First India Newspaper Jaipur.pdf
19032024_First India Newspaper Jaipur.pdf
 
Green Aesthetic Ripped Paper Thesis Defense Presentation_20240311_111012_0000...
Green Aesthetic Ripped Paper Thesis Defense Presentation_20240311_111012_0000...Green Aesthetic Ripped Paper Thesis Defense Presentation_20240311_111012_0000...
Green Aesthetic Ripped Paper Thesis Defense Presentation_20240311_111012_0000...
 
Por estos dos motivos, defensa de JOH solicita repetir juicio
Por estos dos motivos, defensa de JOH solicita repetir juicioPor estos dos motivos, defensa de JOH solicita repetir juicio
Por estos dos motivos, defensa de JOH solicita repetir juicio
 
One India vs United India by Dream Tamilnadu
One India vs United India by Dream TamilnaduOne India vs United India by Dream Tamilnadu
One India vs United India by Dream Tamilnadu
 
Light Rail in Canberra: Too much, too little, too late: Is the price worth th...
Light Rail in Canberra: Too much, too little, too late: Is the price worth th...Light Rail in Canberra: Too much, too little, too late: Is the price worth th...
Light Rail in Canberra: Too much, too little, too late: Is the price worth th...
 
Another Day, Another Default Judgment Against Gabe Whitley
Another Day, Another Default Judgment Against Gabe WhitleyAnother Day, Another Default Judgment Against Gabe Whitley
Another Day, Another Default Judgment Against Gabe Whitley
 
Ministry of Justice Extradition Eswatini 3.pdf
Ministry of Justice Extradition Eswatini 3.pdfMinistry of Justice Extradition Eswatini 3.pdf
Ministry of Justice Extradition Eswatini 3.pdf
 
Anantkumar Hegde
Anantkumar Hegde  Anantkumar Hegde
Anantkumar Hegde
 

Therapeutic class overview treating refractory hematological malignancies - ReportsCorner

  • 1. Reports Corner THERAPEUTIC CLASS OVERVIEW: TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES RC
  • 2. Description Description Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs – Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting in improved survival. www.reportscorner.com Reports Corner
  • 3. Brief Summary Brief Summary Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs – Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting in improved survival. However, eventually all patients relapse and new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) are required to further improve survival and quality of life of this group of pts. Two new drugs have successfully fulfilled this need – POMALYST/ IMNOVID (pomalidomide – POM) and Kyprolis (carfilzomib-CFZ) but is there room for more?We expect a similar scenario to unfold in the treatment of Recurrent/ Refractory MDS (RR-MDS, High-Risk MDS), and Relapsed/ Refractory AML (R/R AML). www.reportscorner.com Reports Corner
  • 4. Brief Summary Brief Summary Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature/nascent product/innovator company at a premium. The report provides an overview of the approved therapies for RRMM, NDMM, AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing these therapy areas – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them. www.reportscorner.com Reports Corner
  • 5. Table of Contents Table of Contents Chapters Title Pg No. 1. Executive Summary 33 2. Disease Overview: MDS 34-35 2.1. Unmet Need: MDS 3. Current Standard of Care 35-36 3.1. Supportive Care: Hematopoietic Cytokine 3.2. Low-Intensity Therapy 3.3. High-Intensity Therapy 3.4. Recurrent / Refractory or relapsed MDS 4. Disease Overview: AML 37 5. Current Standard of Care 37-38 5.1. AML pts Younger than 60 years 5.2. AML pts Older than 60 years 6. Unmet Need: AML 38-39 6.1. Relapsed/ refractory AML www.reportscorner.com Reports Corner
  • 6. Table of Contents Table of Contents 7. Late-Stage pipeline Targeting High-Risk or R/R MDS AND R/R AML 39-48 7.1. Estybon 7.2. Vosaroxin 7.3. Quizartinib 7.4. ADI-PEG 20 7.5. BL-8040 8. Late-Stage pipeline Targeting 1st-line Lower Risk MDS 49-51 8.1. Volasertib 8.2. CPX-351 8.3. Sapacitabine 8.4. Oral Rigosrtib 9. Key Milestones of Drugs For RRMDS/RRAML in 2014-15 52 10. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline (RR MDS and RR AML) 53 11. Drivers of M&A/Licensing Deals in MDS/AML 54 www.reportscorner.com Reports Corner
  • 7. For more information For more information For more information please visit our website https://www.reportscorner.com/reports/37924/-THERAPEUTIC-CLASS-OVERVIEW:TREATING-REFRACTORY-HEMATOLOGICAL-MALIGNANCIES/ www.reportscorner.com Reports Corner
  • 8. RC Thank You Thank You Contact us: contact@reportscorner.com www.reportscorner.com Reports Corner